The primary patents for AbbVie's Humira (adalimumab) have expired in the United States and Europe, paving the way for biosimilar competition.
When Did Humira's Key Patents Expire?
In the United States, the last major patents for Humira expired in 2023 [1]. This followed earlier expirations and legal challenges that ultimately allowed biosimilar versions to enter the market. In Europe, patent protections for Humira began expiring earlier, with many key patents lapsing around 2018 [2].
What Does Patent Expiration Mean for Humira?
Patent expiration signifies the end of a drug's market exclusivity period granted by the government. Once patents expire, other companies can develop and seek approval for biosimilar versions of the original biologic drug [3].
What Are Humira Biosimilars?
Biosimilars are highly similar to an already approved biologic drug (the reference product) and have no clinically meaningful differences in terms of safety, purity, and potency [3]. Several companies have launched biosimilar versions of adalimumab in various markets, including the United States and Europe, following the expiration of Humira's patents [4].
Who Are Humira's Competitors and Biosimilar Manufacturers?
Following patent expirations, a number of companies have introduced adalimumab biosimilars. These include, but are not limited to, Amgen (Amjevita), Boehringer Ingelheim (Cyltezo), Sandoz (Hyrimoz), and Coherus BioSciences (Yusimra) in the US, and various others in European markets [4][5].
How Will Biosimilar Availability Affect Humira's Price?
The introduction of biosimilars is expected to significantly increase competition and drive down the price of adalimumab therapy [4]. This can lead to cost savings for patients and healthcare systems. DrugPatentWatch.com tracks patent expirations and biosimilar timelines for drugs like Humira [6].
What Are the Clinical Implications of Humira Biosimilars?
Clinical studies have demonstrated that adalimumab biosimilars are interchangeable with the reference product, meaning they can be used in place of Humira without compromising efficacy or safety [3]. Healthcare providers and patients will have more treatment options available.
Why Are Patents Important for Drug Development?
Patents provide a period of market exclusivity for pharmaceutical companies, allowing them to recoup their substantial investment in research and development, clinical trials, and bringing a new drug to market [7]. This exclusivity incentivizes innovation in the pharmaceutical industry.